PicoCELA Inc. (NASDAQ:PCLA) Sees Large Growth in Short Interest

PicoCELA Inc. (NASDAQ:PCLA) was the recipient of a large growth in short interest during the month of June. As of June 30th, there was short interest totaling 113,864 shares, a growth of 206.2% from the June 15th total of 37,187 shares. Based on an average daily volume of 822,239 shares, the days-to-cover ratio is currently 0.1 days. Currently, 284.7% of the company’s stock are short sold.

PicoCELA Trading Up 0.2%

NASDAQ:PCLA traded up $0.01 during mid-day trading on Monday, hitting $4.77. The stock had a trading volume of 40,771 shares, compared to its average volume of 789,875. PicoCELA has a twelve month low of $1.35 and a twelve month high of $112.20. The company’s 50 day simple moving average is $4.87 and its 200 day simple moving average is $4.72.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of PicoCELA in a research note on Monday, July 6th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

Institutional Trading of PicoCELA

An institutional investor recently bought a new position in PicoCELA stock. Jane Street Group LLC bought a new position in shares of PicoCELA Inc. (NASDAQ:PCLA) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 172,132 shares of the company’s stock, valued at approximately $52,000. Jane Street Group LLC owned 18.92% of PicoCELA at the end of the most recent quarter.

PicoCELA Company Profile

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.